Effective bio-decontamination is an essential step in sterile drug manufacturing, for regulatory compliance and for product and patient protection. Biological indicators (BIs) have long served as the gold standard for evaluating bio-decontamination efficacy. The indicators are strategically placed inside an isolator to determine whether the process has been effective in deactivating the BI spores at different locations, thus providing confidence in the approach.
However, hydrogen peroxide (H₂O₂) distribution during decontamination is not uniform across the isolator. Often, BIs are placed according to perception of risk such as geometric locations or in the areas that are easiest to physically access, rather than according to systematic data on strategic testing positions. Furthermore, BIs are limited in their insights, providing only pass/fail data rather than helping to determine the cause of the failure.
Ultimately, regulatory guidance such as the EU GMP Annex 1, ISO 14644-5, and EN 17141 emphasise the importance of a risk-based, data-informed approach to BI location selection and Contamination Control Strategy (CCS), which periodic BI testing alone is not adequately equipped to support. Enzyme indicators (EIs) help bridge this gap by providing rapid, quantitative data to inform BI placement and establish a more defensible validation package.
The challenge locations falling off the radar
H₂O₂ distribution is influenced by factors such as isolator size, shape, load pattern, glove ports, transfer chambers, and other features that affect airflow. Glove and sleeve ports are among the most commonly overlooked challenge locations, along with sampling areas and the spaces between vials, all of which can contribute to ineffective bio-decontamination. Thoroughly evaluating these locations with BIs, however, presents practical challenges. BIs require seven days of incubation, making the testing of multiple positions during cycle development a time-consuming process. Moreover, obtaining meaningful confirmation typically requires three BIs per test location, which, due to their size, limits the number of testing locations that can be assessed within an isolator.
BIs can only provide accurate contamination insights into the locations chosen to test; if a location is not assessed, a passing result offers no insight into its sterility. When EIs are placed in additional locations, they often identify new areas with poor airflow and H₂O₂ distribution.
While computational fluid dynamics (CFD) modelling and airflow visualisation can help predict H₂O₂ challenges, EI data can further prove and support CFD models. If a user has never leveraged a quantitative tool to map H₂O₂ distribution, they are likely carrying uncharacterised risk in untested positions. By identifying challenge locations earlier in cycle development, users can reduce troubleshooting time and costs while providing regulators with a clear, data-driven rationale for their BI placement strategy.
The power of a hybrid approach
Despite the speed and quantitative insights of EIs, Annex 1 states that it is prudent and conservative to use BIs in final process performance qualification (PPQ). However, it also encourages continuous system monitoring, leveraging insight from other systems, and taking a data-driven approach. Without EI to inform BI location selection, contamination will only be flagged in the event of BI failure, which likely means that significant time and product have already been wasted.
Enter the hybrid solution: using EIs across multiple positions in initial runs to secure a quantitative picture of H₂O₂ distribution variability. EIs are small and provide rapid, same-day results as opposed to the binary, seven-day turnaround of BIs. As a result, users significantly cut troubleshooting time in cycle development and leverage EI data to support earlier cycle optimisation. Once challenge locations are identified and characterised, BI placement decisions will be evidence-based rather than assumption-based. Annex 1 also requires the demonstration of repeatability. With BIs, repeatability only goes so far as a passing result. Yet, with EIs, results have actual data values, allowing users to more accurately compare cycle repeatability.
Additionally, because EIs are non-viable, they are safe to be present in a routine cycle to support continuous cycle monitoring. A current limitation in pharma facility safety is the lack of monitoring around gas cycles, which only have annually mandated periodic requalification. To mitigate the risk of sterilisation failure, EIs could be routinely placed in challenging locations to provide an accurate read on how the H₂O₂ bio-decontamination cycle is performing. If a monitored run reports failed locations, users can prevent contaminated production isolators from being used to manufacture product.
Protect your product, protect your patients
While BIs have long been the industry standard for evaluating bio-decontamination cycles, technologies that make contamination detection faster, cheaper, quantifiable, and less cumbersome continue to evolve. To build a risk-based, Annex 1-compliant BI placement strategy, consider incorporating EIs to address the limitations of BIs. Together, EIs and BIs provide a complementary approach that helps users identify challenge locations with greater confidence, strengthen validation packages, and better protect bio-decontamination cycles.
We support teams from early cycle development through qualification and ongoing lifecycle oversight.
